Opus Genetics Inc (IRD) Stock Price, Quote & News

Company Profile

Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of inherited retinal diseases (IRDs). It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets autosomal do...

Industry: Biotechnology

Sector: Healthcare

Phone: 984 884 6030

Website: opusgtx.com

Address:

8 Davis Drive, Suite 220, Durham, United States

signaljumper Dec. 4 at 8:31 PM

$IRD 2.32 is the key to close above to See 3$+

0 · Reply

DGains Dec. 4 at 4:26 PM

$RYCEY Rolls-Royce Chillin’! 🏎️ $IRD Heating UP 🔥🛫 Volume Soon and $BYND Go Beyond! 💹 $META Beast Mode! 🦍

0 · Reply

Um8a123 Dec. 3 at 5:39 PM

$IRD

0 · Reply

alexquick123 Dec. 3 at 2:02 PM

$IRD just drop like you always do, your not him, let’s be honest. I need to reload my shares.

0 · Reply

signaljumper Nov. 28 at 4:58 PM

$IRD 2.32 IS the key to Close above in the next days to See 3 bucks

0 · Reply

TheAliAbdul Nov. 28 at 3:52 PM

$IRD Next resistance at $2.15 and then all the way to $2.37?

0 · Reply

JarvisFlow Nov. 25 at 2:22 PM

Piper Sandler has updated their rating for Opus Genetics ( $IRD ) to Overweight with a price target of 7.

0 · Reply

TheAliAbdul Nov. 20 at 4:21 PM

$IRD Needs to breakthrough resistance at $2.03, if it keeps getting rejected here I think we see $1.60-1.50

1 · Reply

RCO234 Nov. 19 at 2:26 AM

$IRD Don’t want to jinx it but seems to be holding.

0 · Reply

Maynard_Keysian Nov. 17 at 10:49 PM

$IRD Sold most, agree with others on a pullback, looking to get back in $1.10 to $1.50.

1 · Reply

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 20, 2025, 8:00 AM EST - 14 days ago

Opus Genetics to Participate in Upcoming Investment Conferences

Nov 13, 2025, 7:00 AM EST - 21 days ago

Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease

Nov 12, 2025, 7:00 AM EST - 22 days ago

Opus Genetics Announces Financial Results for Third Quarter 2025 and Provides Corporate Update

Nov 6, 2025, 7:00 AM EST - 4 weeks ago

Opus Genetics Announces $23 Million Registered Direct Offering

Nov 6, 2025, 7:00 AM EST - 4 weeks ago

Opus Genetics Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal Disease

Oct 14, 2025, 8:00 AM EDT - 7 weeks ago

Opus Genetics to Participate in Chardan's 9th Annual Genetic Medicines Conference

Oct 2, 2025, 8:00 AM EDT - 2 months ago

Opus Genetics to Present at Upcoming Medical and Industry Conferences in October 2025

Sep 30, 2025, 12:12 PM EDT - 2 months ago

Opus Genetics, Inc. - Special Call

Sep 30, 2025, 7:00 AM EDT - 2 months ago

Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)

$Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions$

Sep 4, 2025, 8:00 AM EDT - 3 months ago

Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions

Sep 3, 2025, 8:00 AM EDT - 3 months ago

Opus Genetics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 8:00 AM EDT - 3 months ago

Opus Genetics Appoints Rob Gagnon as Chief Financial Officer

Aug 27, 2025, 8:00 AM EDT - 3 months ago

Opus Genetics Inherited Retinal Disease Programs Featured at Medical and Industry Conferences in September

Aug 18, 2025, 8:00 AM EDT - 3 months ago

Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1

Aug 13, 2025, 4:30 PM EDT - 4 months ago

Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update

Aug 5, 2025, 8:00 AM EDT - 4 months ago

Opus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Jul 23, 2025, 8:00 AM EDT - 4 months ago

Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindness

Jul 3, 2025, 4:30 PM EDT - 5 months ago

Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 26, 2025, 6:55 AM EDT - 5 months ago

Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

Jun 23, 2025, 8:00 AM EDT - 5 months ago

Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program

$Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions$

Jun 2, 2025, 8:00 AM EDT - 6 months ago

Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions

May 15, 2025, 8:00 AM EDT - 7 months ago

Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update

May 12, 2025, 8:00 AM EDT - 7 months ago

Opus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in May

May 6, 2025, 8:00 AM EDT - 7 months ago

Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate

May 5, 2025, 8:00 AM EDT - 7 months ago

Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision

Apr 11, 2025, 3:47 PM EDT - 8 months ago

Founder Mina Sooch Issues Open Letter to Opus Genetics Stockholders Following Withdrawal of the Restore Value Slate Amid Dilutive Financing and Governance Concerns

Apr 8, 2025, 8:00 AM EDT - 8 months ago

Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases

Apr 2, 2025, 8:00 AM EDT - 8 months ago

Opus Genetics to Participate in Upcoming Investor Conference in April

Mar 31, 2025, 8:20 AM EDT - 8 months ago

Opus Genetics Announces Financial Results for Full Year 2024

Mar 21, 2025, 5:03 PM EDT - 9 months ago

Restore Value Slate Led by Mina Sooch Files Preliminary Proxy Materials for the Election of Six Highly Qualified Directors at the 2025 Annual Meeting of Opus Genetics

Mar 21, 2025, 9:30 AM EDT - 9 months ago

Opus Genetics Announces Presentation on Phentolamine Ophthalmic Solution 0.75% in Dim Light Disturbances at World Cornea Congress IX

Mar 21, 2025, 9:11 AM EDT - 9 months ago

Opus Genetics Announces Pricing of Public Offering and Concurrent Private Placement with Proceeds of Over $20 Million

Mar 5, 2025, 8:00 AM EST - 9 months ago

Opus Genetics Announces Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting

Feb 26, 2025, 8:00 AM EST - 10 months ago

Opus Genetics Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs

Feb 18, 2025, 7:30 AM EST - 10 months ago

Opus Genetics Announces Updates on OPGx-LCA5 Clinical Program

Feb 7, 2025, 9:15 AM EST - 10 months ago

Shareholder Group Led by Founder Mina Sooch Nominates Majority Slate of Director Candidates to the Board of Opus Genetics, Inc.

XBI

Dec 19, 2024, 8:00 AM EST - 1 year ago

Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy

signaljumper Dec. 4 at 8:31 PM

$IRD 2.32 is the key to close above to See 3$+

0 · Reply

DGains Dec. 4 at 4:26 PM

$RYCEY Rolls-Royce Chillin’! 🏎️ $IRD Heating UP 🔥🛫 Volume Soon and $BYND Go Beyond! 💹 $META Beast Mode! 🦍

0 · Reply

Um8a123 Dec. 3 at 5:39 PM

$IRD

0 · Reply

alexquick123 Dec. 3 at 2:02 PM

$IRD just drop like you always do, your not him, let’s be honest. I need to reload my shares.

0 · Reply

signaljumper Nov. 28 at 4:58 PM

$IRD 2.32 IS the key to Close above in the next days to See 3 bucks

0 · Reply

TheAliAbdul Nov. 28 at 3:52 PM

$IRD Next resistance at $2.15 and then all the way to $2.37?

0 · Reply

JarvisFlow Nov. 25 at 2:22 PM

Piper Sandler has updated their rating for Opus Genetics ( $IRD ) to Overweight with a price target of 7.

0 · Reply

TheAliAbdul Nov. 20 at 4:21 PM

$IRD Needs to breakthrough resistance at $2.03, if it keeps getting rejected here I think we see $1.60-1.50

1 · Reply

RCO234 Nov. 19 at 2:26 AM

$IRD Don’t want to jinx it but seems to be holding.

0 · Reply

Maynard_Keysian Nov. 17 at 10:49 PM

$IRD Sold most, agree with others on a pullback, looking to get back in $1.10 to $1.50.

1 · Reply

TruthTooPower Nov. 17 at 8:40 PM

$IRD Ok Guyz? What Is Our Price Target for the EOW? I Got $2.47!!!!!!!!!!!!!!!!!!

2 · Reply

JoeD32 Nov. 17 at 7:41 PM

$IRD this will hit $1 before it hits $2 again

0 · Reply

MachoNacho22 Nov. 13 at 8:02 PM

Forget beta — $IRD is chasing alpha by tackling one of medicine’s biggest challenges: curing blindness. Real science, real impact. 👁️🔥 #Biotech #Alpha OHHH YEEEEAH

0 · Reply

MachoNacho22 Nov. 13 at 2:44 PM

$IRD $IRD kicking off the OPGx-NEST1 Phase 1/2 trial with its first patient dosed ✅ Big day for the team — could be the start of serious traction in gene therapy. 👀🔥 #Biotech #SmallCaps

0 · Reply

TheAliAbdul Nov. 13 at 1:52 PM

$IRD https://stocks.apple.com/A0Km7yNmQQC6wwI4fsG5A3w

0 · Reply

JarvisFlow Nov. 13 at 1:42 PM

Chardan Capital has adjusted their stance on Opus Genetics ( $IRD ), setting the rating to Buy with a target price of 9.

0 · Reply

microactivist Nov. 13 at 1:19 PM

$IRD quietly building one of the cleaner gene-therapy pipelines in the microcap space. Funny how the market gets bored until the data shows up… then suddenly everyone “always loved the story.”

0 · Reply

signaljumper Nov. 13 at 8:47 AM

$IRD loading more at this Level. I Like the consolidation very healthy after a 100% Run . If WE will Breakout again than i See again a 100% Run north

0 · Reply

d_risk Nov. 12 at 4:25 PM

$IRD - Opus Genetics, Inc. - 10Q - Updated Risk Factors IRD flags new risks: limited ability to issue more stock for financing, potential delays from government agency disruptions like FDA, and expanded details on Nasdaq listing threats including delisting process and impacts on liquidity and capital access. #Biotechnology #MarketLiquidity #NasdaqListing #StockFinancing #RegulatoryRisk 🟢 Added 🟠 Removed https://d-risk.ai/IRD/10-Q/2025-11-12

0 · Reply

n43 Nov. 12 at 1:53 PM

$IRD drop it down. I need to lower my average for the run up next year

0 · Reply

TheAliAbdul Nov. 12 at 1:44 PM

$IRD going to be a very red day I imagine.

0 · Reply

alexquick123 Nov. 12 at 1:17 PM

$IRD what you know , another offering. Milk it dry as they say

0 · Reply

Market Cap	144.14M
Revenue (ttm)	10.99M
Net Income (ttm)	-57.53M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-523.48%
Debt to Equity Ratio	0.18

Volume	382,800
Avg Vol	479,612
Day's Range	N/A - N/A
Shares Out	68.96M
Stochastic %K	86%
Beta	0.42
Analysts	Strong Sell
Price Target	$7.62